Results 31 to 40 of about 1,923,383 (256)
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Nature reviews. Drug discovery, 2023 Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic approach for the treatment of patients with chemotherapy-refractory or relapsed blood cancers, including acute lymphoblastic leukaemia, diffuse large B cell lymphoma,
M. Ruella +3 more
semanticscholar +1 more source
Tumor Biology, 2017 Chimeric antigen receptor modified T cell–based immunotherapy is revolutionizing the field of cancer treatment. However, its potential in treating bile duct carcinoma has not been fully explored.
Jie-Ying Xu +9 more
doaj +1 more source
Journal of Medical Case Reports, 2022 Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory ...
Bai-Yan Wang +20 more
doaj +1 more source
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2023 Chimeric antigen receptor (CAR) T-cells are a cellular immunotherapy with remarkable efficacy in treating multiple hematologic malignancies but they are associated with extremely high prices that are, for many countries, prohibitively expensive. As their
Edward R. Scheffer Cliff +6 more
semanticscholar +1 more source
Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the a-chain of the human interleukin-2 receptor [PDF]
, 1992 The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 ...
Schwirzke, Marina +10 more
core +1 more source
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Journal of Hematology & Oncology, 2021 Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are considered as specialized immune cells that can be genetically modified to obtain capable effector cells for adoptive cellular treatment of cancer patients ...
Ying Gong +4 more
semanticscholar +1 more source
Haematologica, 2016 Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for antibody therapy.
Esther Drent +13 more
doaj +1 more source
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
Science Advances, 2023 Incomplete surgery of solid tumors is a risk factor for primary treatment failure. Here, we have investigated whether chimeric antigen receptor T cells (CARTs) could be used as an adjuvant therapy to clear residual cancer cells. We tested the feasibility
U. Uslu +6 more
semanticscholar +1 more source
Chimeric antigen receptor T cell therapies for thoracic cancers-challenges and opportunities
, 2020 Chimeric antigen receptor T cell therapies for thoracic cancers— challenges and ...
Slaney, CY +4 more
core +1 more source
Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments
Frontiers in Immunology, 2022 Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues ...
Alejandro Ramírez-Chacón +13 more
doaj +1 more source